Nova Biomedical

Nova Biomedical is a technology company specializing in the development of innovative blood gas analyzers and point-of-care testing meters that provide swift and accurate diagnostic results for critical care environments. Founded in 1976 in the US, Nova Biomedical designs and manufactures diagnostic equipment, focusing on blood gas analysis and point-of-care testing. The company has maintained a consistent strategy in its core business without significant pivots. Nova Biomedical operates globally with offices in locations such as Waltham, Massachusetts, and additional international offices in Australia and Canada.

The company's founder has a history of creating several technology-driven healthcare solutions before establishing Nova. Nova Biomedical specializes in the development, manufacturing, and commercialization of advanced blood gas analyzers and point-of-care testing meters, which deliver rapid and accurate diagnostic results in critical care settings. The flagship StatStrip® series features handheld meters that measure lactate, hemoglobin, hematocrit, glucose, and ketones from capillary blood samples, providing results within seconds. Other notable products include the BioProfile line of cell culture chemistry analyzers, which serve the biotechnology and biopharmaceutical sectors by analyzing various cellular parameters.

Nova's products are utilized in hospitals, clinics, and emergency medical services, with an expanding presence in international markets such as Australia, Canada, and select countries in Europe and Asia. End users include healthcare professionals, sports medicine experts, and researchers who rely on precise and timely test results for informed medical decisions. Nova Biomedical operates on a business-to-business transaction model, primarily selling diagnostic products directly to healthcare facilities and laboratories. The company’s revenue is generated through the sale of analyzers and testing meters, typically acquired via direct purchase agreements or long-term supply contracts with medical institutions.

These transactions often involve one-time equipment sales and ongoing consumables, ensuring continuous revenue streams. Pricing structures align with industry standards for medical devices, with flagship offerings like the StatStrip® glucose and lactate meters serving as key revenue drivers. Nova has established a solid customer base within the critical care sector, positioning itself as a reliable provider of essential diagnostic tools for healthcare professionals globally. Nova Biomedical is focused on enhancing its product lineup with plans to launch new diagnostic solutions by the end of 2024, further strengthening its market presence.

The company aims to expand into new geographic regions, targeting Southeast Asia and Europe for growth over the next five years. Recent funding will be utilized to support research and development of new products, as well as to establish new partnerships in emerging markets, which will help drive the company's future growth initiatives.